Tennessee Oncology-Nashvilee/Sarah Cannon Research Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Burris, Howard
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Completed
1/2
76
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
10/23
06/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
CPI-300, NCT04808453: Phase I Study of in Patients With Advanced Tumors

Completed
1
17
US
CPI-300
Coordination Pharmaceuticals, Inc.
Advanced Tumors
12/23
12/23
RIVER-51, NCT04021368: RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Active, not recruiting
1
112
Europe, US
RVU120(SEL120)
Ryvu Therapeutics SA
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
12/24
12/24
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
NCT03891953: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Active, not recruiting
1
99
Europe, Japan, US, RoW
DKY709, PDR001, Spartalizumab
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
02/25
02/25
BTX-A51-002, NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting
1
112
US
BTX-A51
Edgewood Oncology Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
05/26
05/27
Bendell, Johanna
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
KEYNOTE A60, NCT04332653: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Active, not recruiting
1/2
215
US
NT-I7, Efineptakin alfa, rhIL-7-hyFc, pembrolizumab (KEYTRUDA®), KEYTRUDA®
NeoImmuneTech, Merck Sharp & Dohme LLC
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
11/24
12/24
NCT02740985: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Hourglass Jul 2018 - Dec 2018 : For advanced solid tumours
Completed
1
313
US
AZD4635, Durvalumab, MEDI4736, Abiraterone Acetate, Zytiga, Enzalutamide, Xtandi, Oleclumab, MEDI9447, Docetaxel, Taxotere
AstraZeneca
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
12/20
03/23
Smith, Andrea
NCT04485728: Sleep Improvement Intervention for Hospitalized Antepartum Patients

Completed
N/A
40
US
Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients
Sam Houston State University, The University of Texas Health Science Center, Houston, Memorial Hermann Texas Medical Center
Sleep Disturbance in Hospitalized Antepartum Patients
07/22
01/23

Download Options